Navigation Links
Current and Emerging Drugs Have No Advantage Over Enbrel in Inhibiting/Slowing the Progression of Rheumatoid Arthritis
Date:4/7/2008

Although Some Emerging Therapies Hold Promise, Enbrel Will Remain the

Clinical Gold Standard Through 2016, According to a New Report from

Decision Resources

WALTHAM, Mass., April 7, 2008 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that a drug's effect on inhibiting/slowing the progression of structural damage and reducing the signs and symptoms of rheumatoid arthritis during the first year of treatment are the attributes that most influence surveyed rheumatologists' prescribing decisions in the treatment of the disease. Clinical data and expert opinion shows that current and emerging therapies have no advantage in these attributes over the market sales leader, Amgen/Wyeth/Takeda's Enbrel.

The new report entitled Rheumatoid Arthritis: Competitive, Crowded Market Sets the Bar High for Novel Agents finds that, through 2016, there are no therapies in development that will displace Enbrel as the clinical gold standard treatment for rheumatoid arthritis. While some therapies in development for the disease hold promise, most have efficacy, safety and tolerability, and/or delivery features that are inferior when compared with Enbrel.

The overall efficacy of emerging therapies such as Centocor/Schering-Plough/Mitsubishi Tanabe/Janssen's golimumab and Biogen Idec/Genentech/Roche's ocrelizumab is comparable to that of Enbrel, while the overall safety and tolerability for emerging therapies that include ocrelizumab and UCB's Cimzia are also comparable to that of Enbrel. However, the currently available clinical data for golimumab, ocrelizumab and Cimzia is not as robust or extensive as those available for Enbrel.

"While emerging therapies such as golimumab and Cimzia offer superior delivery to that of Enbrel due to improved dosing frequencies, these agents' overall efficacy, safety and tolerability, respect
'/>"/>

SOURCE Decision Resources, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. CV Therapeutics Anti-Ischemic Therapy Ranexa(R) Significantly Reduces Cardiac Chest Pain Symptoms and Recurrent Ischemia in MERLIN-TIMI 36 Patients With Angina
2. Jazz Pharmaceuticals, Inc. Announces Receipt of FDA Orphan Drug Designation for Recurrent Acute Repetitive Seizures Product Candidate
3. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
4. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
5. Rib-X Pharmaceuticals to Present at 10th Annual Superbugs & Superdrugs Conference
6. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
7. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
8. Micromet Announces the Publication of BiTE Antibody Review in Drugs of the Future
9. Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
10. First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs
11. Surface Logix Presents Positive Phase 1 Repeat-Dose Trial Data on SLx-4090 at The 16th International Symposium on Drugs Affecting Lipid Metabolism
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... BARBARA, Calif. , Dec. 23, 2014 In ... Junior Doctors, Association of Sierra Leone , ... Sierra Leone for the treatment of local health ... While a new dedicated Ebola care center was constructed ... virus, the facility is not available for local Sierra Leonean ...
(Date:12/22/2014)... Dec. 22, 2014  CytoSorbents Corporation (OTCQB:CTSOD), a ... blood purification technology to help fight deadly inflammation ... countries worldwide, today announced the appointment of Dr. ... as its Senior Vice President of Clinical Development, ... Di Russo is an accomplished pediatric ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... the "US Self-monitoring Blood Glucose Market" report ... This market insight focuses on the ... the United States . Reimbursement analysis and ... product analyses for more than 73 SMBG meters have ...
Breaking Medicine Technology:First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 2CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 3CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 4CytoSorbents Appoints Dr. Gregory B. Di Russo as Senior Vice President of Clinical Development 5US Self-monitoring Blood Glucose Market 2
... , , MONMOUTH JUNCTION, ... from a Phase II clinical trial in non-cystic fibrosis (CF) ... (liposomal amikacin for inhalation). The Phase II data indicated that ... clinical benefit compared to placebo as measured by patient and ...
... , TARRYTOWN, N.Y., Sept. 14 ... announced the completion of patient enrollment in two randomized, double-masked, ... of the neovascular form of age-related macular degeneration (wet AMD). ... of Efficacy and Safety in Wet AMD) program, VEGF Trap-Eye ...
Cached Medicine Technology:Transave Announces Positive Phase II Results For Once-Daily ARIKACE(TM) in the Treatment of Non-CF Bronchiectasis Patients Who Have Pseudomonas Lung Infections 2Transave Announces Positive Phase II Results For Once-Daily ARIKACE(TM) in the Treatment of Non-CF Bronchiectasis Patients Who Have Pseudomonas Lung Infections 3Transave Announces Positive Phase II Results For Once-Daily ARIKACE(TM) in the Treatment of Non-CF Bronchiectasis Patients Who Have Pseudomonas Lung Infections 4Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD) 2Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD) 3Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD) 4Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD) 5
(Date:12/26/2014)... December 26, 2014 Pentec Health, Inc. ... the state of Pennsylvania for 2014. The awards program, ... programs of its kind in the country. The program ... Pennsylvania Department of Community and Economic Development, the Pennsylvania ... and the Central Penn Business Journal. , ...
(Date:12/26/2014)... Parker & Sons, Inc. a ... heating, cooling and plumbing contractor services throughout Arizona ... in 2014 with regard to air-conditioning systems. Residential ... known for its incredibly hot summers. Working with ... and details of a wide variety of systems ...
(Date:12/25/2014)... This is a professional and in-depth study ... with a focus on the Chinese market. The report ... Sterilizers manufacturers and is a valuable source of guidance ... industry. This report provides a basic overview of the ... this part, the report presents the company profile, product ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... and Market Analysis to 2023” focuses on the ... commercial opportunities in the colorectal cancer market. Stivarga ... treatment of colon or rectal cancer. Boehringer Ingelheim ... inhibitor, for the treatment of refractory CRC in ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Product liability ... ASR hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move ... to an Order issued in the U.S. District Court, ... will convene an open conference on January 7, 2015, ... States Courthouse in West Palm Beach, Florida. The Conference ...
Breaking Medicine News(10 mins):Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 2Health News:Parker & Sons Announces Record Demand For 24 Hour Emergency Services In 2014 With Regard To Air-Conditioning Systems 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3
... Queen et al. Patents for Soliris(R) INCLINE VILLAGE, Nev., and ... PDLI ) and Alexion Pharmaceuticals, Inc. (Nasdaq: ... have entered into a definitive license agreement and settlement agreement ... humanized antibody, Soliris(R) (eculizumab) and PDL,s patents known as the ...
... Jan. 5 The Ensign Group, Inc. (Nasdaq: ... has acquired Southland Healthcare Center, a 150-bed skilled ... effective January 1, 2009. The facility has been ... http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO )"This is a strategic acquisition, and ...
... The Ensign Group, Inc. (Nasdaq: ... Cabrillo Care Center, a 156-bed skilled nursing facility ... effective January 1, 2009. The facility has been ... http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO )"We are excited to extend our ...
... Campaign of Upscale Properties in Denver, Colorado , ... ... estate auction marketing firm, LFC Group of Companies, launched a new ... residential real estate website, Freedom Realty Exchange ( FRE.com/284R3 ). The ...
... Help us, help the Red Cross meet the winter demand for blood. January ... Wilmington MA. We,ll give you FREE oil change if you,re one of the first ... ... the American Red Cross are asking people to come out and give blood as ...
... informatics platform, OnCore®, achieved another milestone this ... multidisciplinary research organization. At the end of ... Clinical and Translational Research (UWICTR) began using ... collection and administration needs. OnCore is the ...
Cached Medicine News:Health News:Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute 2Health News:Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute 3Health News:The Ensign Group Acquires Texas Skilled Nursing Facility 2Health News:The Ensign Group Acquires California Skilled Nursing Facility 2Health News:Let the Bidding Begin in Online Auction of Denver Luxury Homes 2Health News:Let the Bidding Begin in Online Auction of Denver Luxury Homes 3Health News:Let the Bidding Begin in Online Auction of Denver Luxury Homes 4Health News:Boston Hyundai Dealer Teams up With the Red Cross to Save Lives 2Health News:OnCore System Supporting Research Informatics Needs of the University of Wisconsin's Institute for Clinical and Translational Research 2Health News:OnCore System Supporting Research Informatics Needs of the University of Wisconsin's Institute for Clinical and Translational Research 3Health News:OnCore System Supporting Research Informatics Needs of the University of Wisconsin's Institute for Clinical and Translational Research 4
Gentle-Flo® Standard Connector., ,Indications For Usage: ,Removal of secretions from respiratory tract....
... Increase Staff Protection With Medline's Sterile Suction Catheters ... 16 Fr and 18 Fr), ,Medline is ... U.S. We manufacture most of our suction products ... our customers' expectations. We manufacture, supply and directly ...
... Catheters are available in ... atraumatic DeLee tip with staggered ... tip. Two types of catheter ... deliver easy fingertip control with ...
... Catheters are available in two ... DeLee tip with staggered eyes, ... Two types of catheter valve ... easy fingertip control with virtually ...
Medicine Products: